Is Your Patient Eligible?

Oncotype DX GPS patient - Lloyd

Your patients with clinically localized prostate cancer might be candidates for the Oncotype DX Genomic Prostate Score (GPS) test.

The Oncotype DX Genomic Prostate Score assay is intended for patients with:

icon Biopsy within 3 years

icon Not started treatment

icon Localized prostate cancer


Patients with National Comprehensive Cancer Network® (NCCN®) very low-, low, intermediate-, and high-risk disease are eligible.

Very Low
    Has all of the following:
  • T1c
  • Grade Group 1
  • PSA <10 ng/mL
  • Fewer than 3 prostate biopsy fragments/cores positive, ≤50% cancer in each fragment/coree
  • PSA density <0.15 ng/mL/g
    Has all of the following but does not qualify for very low risk:
  • T1-T2a
  • Grade Group 1
  • PSA <10 ng/mL
    Has all of the following:
  • No high-risk group features
  • No very-high-risk group features
  • Has one or more intermediate risk factors (IRF):
    • T2b-T2c
    • Grade Group 2 or 3
    • PSA 10-20 ng/mL
Favorable intermediate

Has all of the following:

  • 1 IRF
  • Grade Group 1 or 2
  • <50% biopsy cores positivee
Unfavorable intermediate

Has one or more of the following:

  • 2 or 3 IRFs
  • Grade Group 3
  • ≥50% biopsy cores positivee
    Has no very-high-risk features and has exactly one high-risk feature:
  • T3a OR
  • Grade Group 4 or Grade Group 5 OR
  • PSA >20 ng/mL
Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2020. ©2020 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines®, go online to The NCCN Guidelines® are a work in progress that may be refined as often as new significant data becomes available.

Insurance and financial assistance

The Oncotype DX GPS test is covered by Medicare (for NCCN very low-, low-, intermediate-, and high-risk prostate cancer). Private insurance coverage varies. To help patients navigate insurance and other payment options for Oncotype DX testing, Exact Sciences offers the Genomic Access Program (GAP) and detailed information about financial assistance. Email Customer Service or call us 866-ONCOTYPE (866-662-6897).


African-American Data in Clinical Studies

Learn more about how the Oncotype DX GPS test can help make more informed treatment decisions in racially diverse populations.


e. An ultrasound- or MRI- or DRE-targeted lesion that is biopsied more than once demonstrates cancer (regardless of percentage core involvement or number of cores involved) counts as a single positive core.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V2.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed June 1, 2020. To view the most recent and complete version of the guideline, go online to

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN and NCCN Guidelines are registered trademarks of the National Comprehensive Cancer Network. NCCN does not endorse any therapy or product.

Making cancer care smarter.®

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.